{
    "nctId": "NCT02954055",
    "briefTitle": "MEtronomic TrEatment Option in Advanced bReast cAncer",
    "officialTitle": "A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 140,
    "primaryOutcomeMeasure": "Time to Treatment Failure (TTF) Compared Between Treatment Groups.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed HER2-negative locally advanced or metastatic (stage IV) breast cancer.\n* Maximum of one prior line of chemotherapy for advanced or metastatic breast cancer.\n* Measurable or non-measurable, but radiologically evaluable (except for skin lesions), disease according to RECIST 1.1 criteria.\n* Female aged 18 years or older.\n* Life expectancy \\> 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* ER-positive disease by local laboratory, determined on most recent available tissue (latest biopsy of metastatic lesion, otherwise prior biopsy or surgical specimen).\n* If previously treated with a taxane in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been \\> 12 months (\\> 365 days).\n* Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.\n* Normal hematologic status,\n* Absolute neutrophil count \u22651000/mm3 (1.0 \u00d7 109/L),\n* Platelets \u2265 100 \u00d7 109/L,\n* Hemoglobin \u2265 9 g/dL (\u2265 90 g/L).\n* Normal renal function: serum creatinine \u2264 1.5 ULN or calculated creatinine clearance \u2265 50 mL/min according to the Cockcroft-Gault formula.\n* Normal liver function:\n* Serum total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\\< 3 \u00d7 ULN) is allowed.\n* Aspartate transaminase (AST) and Alanine transaminase (ALT) \u2264 3 \u00d7 ULN; if the patient has liver metastases, ALT and AST must be \u2264 5 \u00d7 ULN.\n* Women of child bearing potential must have documented negative pregnancy test within 2 weeks prior to randomization and agree to acceptable birth control (non-hormonal) during and up to 6 months after trial therapy.\n* Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to starting screening procedures and randomization.\n* The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.\n\nExclusion Criteria:\n\n* More than one prior line of chemotherapy for advanced or metastatic breast cancer\n* Previous treatment for advanced or metastatic disease with taxanes, or capecitabine or vinorelbine or oral cyclophosphamide.\n* More than 2 lines of previous endocrine therapy for locally advanced or metastatic breast cancer.\n* Known active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of Central Nervous System (CNS) metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of trial treatment and have not required high-dose steroid treatment in the last 4 weeks).\n* Peripheral neuropathy grade 2 or higher (CTCAE version 4.0).\n* Significant uncontrolled cardiac disease (i.e. unstable angina, myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.\n* Pregnant or lactating.\n* Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).\n* Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.\n* Contraindications or known hypersensitivity to the trial medication or excipients.\n* The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}